News

EULAR’s fibromyalgia guidelines provide comprehensive recommendations for managing active fibromyalgia to assist clinicians in making informed decisions. Test your knowledge with this quiz.

This post-hoc analysis of phase 3 data, using GRAPPA-recognized PsA domains, highlighted disease improvements following treatment with guselkumab.

A study found MRI treat-to-target strategy does not help bring RA patients to remission, even when also targeting the absence of osteitis alongside clinical remission.

Without controlling for the severity of symptoms, patients with either fibromyalgia or RA performed worse when compared with controls in terms of cognitive domains including verbal memory, visual memory, and strategic planning.

Despite these conclusions, this meta-analysis also showed that those receiving PDE4 inhibitors were the least likely to report adverse events.

Alkaline water significantly reduced VAS pain scores among patients with gout.

Five barriers to adopting TNF therapeutic drug monitoring emerged among a cohort of experienced rheumatologists.

For those with a family history of gout, the proportion of grade ≥ 2 left ventricular diastolic insufficiency was markedly higher compared with patients without family history.

The median survival for triple therapy was longer compared with double therapy (15.1 months vs 9.6 months).

Obesity was linked to a lower likelihood of obtaining response to treatment during the 48-week follow-up period.

Patients with gout who had poor health literacy were more likely to experience ≥ 2 flares within the previous 12 months.

Katie Abouzahr, MD, explains the transformative potential of nipocalimab for the treatment of patients with autoantibody-driven conditions.

Patients with higher disease activity reported the highest perceived consequence of disease.

The first guideline for the management of osteoporosis in men provides recommendations for diagnosis, monitoring, and treatment.

This month’s rheumatology month in review showcases the efficacy of various medications for the treatment of psoriatic arthritis, underscores the importance of addressing workforce challenges, and explores non-pharmacological interventions.

Exercise was beneficial in functional status for both patients with RA and spondyloarthritis.

Results offer important guidance for healthcare providers to develop tailored treatment strategies that align with the unique needs and preferences of individual patients.

Birthweight was significantly lower in women who were not treated with a TNF.

Gut microbiota-based treatment relieved pain for patients with fibromyalgia.

Kenneth Saag, MD, explores the clinical significance of a study demonstrating treatment with pegloticase leads to bone remodeling in patients with gout.

At week 52, investigators noted an overall improvement of 93% in PASI scores from baseline.

Mohamed Cherry, MD, and Neil Kramer, MD, shed light on a phase 1 trial using CAR-T cell therapy for SLE and its potential implications for lupus treatment.

The selective, allosteric tyrosine kinase 2 inhibitor demonstrated significant and clinically meaningful improvements in PROs versus placebo in a phase 2 trial of patients with PsA.

These data highlight the changes observed in cytokine levels among both PsA treatment responders and non-responders.

A meta-analysis found febuxostat was linked to a greater risk for acute coronary syndrome and atrial fibrillation than allopurinol among Asian patients with and without gout.

Bimekizumab initiation resulted in greater or comparable efficacy regarding minimal disease activity and achievement of ACR50/70 compared with guselkumab.

Compared with RA, patients with PsA had a higher diagnostic delay and a greater time between the onset of symptoms and the start of treatment.

Psoriatic arthritis and spondyloarthritis occurred earlier in children and adolescents with IBD than in the matched references without IBD.

Receiving methotrexate and leflunomide within the 3 months prior to conception was linked to an increased rate of adverse pregnancy outcomes.

Between 2009 and 2020, the number of rheumatologists increased 23%, from 4557 to 5600.